Comerica Bank’s Humacyte HUMA Stock Holding History

Comerica Bank’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,051	Closed	-$3.27K	–	3757
2024 Q1	$3.27K	Sell	1,051 -1,538	-59%	-$5.17K	﹤0.01%	3428
2023 Q4	$7.35K	Hold	2,589	–	–	﹤0.01%	3227
2023 Q3	$7.59K	Buy	+2,589	New	+$8.57K	﹤0.01%	3256

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Comerica Bank's HUMA Position: Q2 2024 in Review

Comerica Bank sold out of Humacyte (HUMA) in Q2 2024, closing a stake of 1,051 shares — an estimated $3.27K sold.

Comerica Bank first reported a position in HUMA in Q3 2023 and held it in 3 quarters. The position peaked at $7.59K in Q3 2023. 123 funds tracked by Wall St. Rank hold HUMA as of Q2 2024.

Comerica Bank reported no remaining Humacyte position as of Q2 2024 after selling out during the quarter.
Comerica Bank sold 1,051 Humacyte shares in Q2 2024, an estimated $3.27K.
Comerica Bank first reported a position in Humacyte in Q3 2023 and held it in 3 quarters.
Comerica Bank's Humacyte position peaked at $7.59K in Q3 2023.
123 funds tracked by Wall St. Rank held Humacyte as of Q2 2024.

Based on Comerica Bank's 13F filing for Q2 2024, filed 15 Aug 2024.